ipragliflozin
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
IntroductionThe present interim report of the STELLA-LONG TERM study aimed to examine the safety and effectiveness of…
Background We previously reported changes of body composition determined by dual-energy X-ray absorptiometry after treatment with…
Background
The options for the treatment of nonalcoholic steatohepatitis (NASH) are limited. We examined the effects of…
Ipragliflozin, a selective sodium glucose cotransporter 2 (SGLT2) inhibitor, is used for the treatment of type 2 diabetes…
We investigated the factors associated with fatty liver remission via treatment with ipragliflozin. The analysis was obtained…
The sodium-glucose cotransporter 2 (SGLT2) is responsible for most glucose reabsorption in the kidney and has been proposed as a…
We read a recent review on the renoprotective effect of sodiumglucose cotransporter 2 inhibitor (SGLT2i) [1], with a great…
Introduction: Type 2 diabetes is the fastest growing non-communicable chronic disease worldwide. One of the newer treatment…
The Renal sodium-dependent glucose co-transporter 2 (SGLT2) is one of the most promising targets for the treatment of type 2…